Insights

Loading spinner
Gathering insights about Bicara Therapeutics

Bicara Therapeutics Tech Stack

Bicara Therapeutics uses 8 technology products and services including Open Graph, MySQL, Floating UI, and more. Explore Bicara Therapeutics's tech stack below.

  • Open Graph
    Content Management System
  • MySQL
    Database
  • Floating UI
    Javascript Libraries
  • Cisco
    Network Hardware
  • Priority Hints
    Performance
  • Linux
    Programming Languages
  • Adobe Creative Suite
    Visualisation Software
  • HTTP/3
    Web & Portal Technology

Media & News

Bicara Therapeutics's Email Address Formats

Bicara Therapeutics uses at least 1 format(s):
Bicara Therapeutics Email FormatsExamplePercentage
First.Last@bicara.comJohn.Doe@bicara.com
50%
First.Last@bicara.comJohn.Doe@bicara.com
50%

Frequently Asked Questions

What is Bicara Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Bicara Therapeutics's official website is bicara.com and has social profiles on LinkedInCrunchbase.

What is Bicara Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Bicara Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Bicara Therapeutics have currently?

Minus sign iconPlus sign icon
As of December 2025, Bicara Therapeutics has approximately 85 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Cmo, Bicara Therapeutics: D. R.Chief Financial Officer: I. H.Chief Corporate Affairs Officer: J. C. W.. Explore Bicara Therapeutics's employee directory with LeadIQ.

What industry does Bicara Therapeutics belong to?

Minus sign iconPlus sign icon
Bicara Therapeutics operates in the Biotechnology Research industry.

What technology does Bicara Therapeutics use?

Minus sign iconPlus sign icon
Bicara Therapeutics's tech stack includes Open GraphMySQLFloating UICiscoPriority HintsLinuxAdobe Creative SuiteHTTP/3.

What is Bicara Therapeutics's email format?

Minus sign iconPlus sign icon
Bicara Therapeutics's email format typically follows the pattern of First.Last@bicara.com. Find more Bicara Therapeutics email formats with LeadIQ.

How much funding has Bicara Therapeutics raised to date?

Minus sign iconPlus sign icon
As of December 2025, Bicara Therapeutics has raised $165M in funding. The last funding round occurred on Dec 12, 2023 for $165M.

When was Bicara Therapeutics founded?

Minus sign iconPlus sign icon
Bicara Therapeutics was founded in 2020.

Bicara Therapeutics

Biotechnology ResearchMassachusetts, United States51-200 Employees

Bicara Therapeutics is a clinical-stage company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company's dual-action biologics are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy. For more, please visit: bicara.com.

Section iconCompany Overview

Website
bicara.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
51-200

Section iconFunding & Financials

  • $165M

    Bicara Therapeutics has raised a total of $165M of funding over 3 rounds. Their latest funding round was raised on Dec 12, 2023 in the amount of $165M.

  • $25M$50M

    Bicara Therapeutics's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $165M

    Bicara Therapeutics has raised a total of $165M of funding over 3 rounds. Their latest funding round was raised on Dec 12, 2023 in the amount of $165M.

  • $25M$50M

    Bicara Therapeutics's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.